# Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma

> **NCT02242097** · PHASE2 · UNKNOWN · sponsor: **Northwestern University** · enrollment: 37 (actual)

## Conditions studied

- Contiguous Stage II Mantle Cell Lymphoma
- Noncontiguous Stage II Mantle Cell Lymphoma
- Stage I Mantle Cell Lymphoma
- Stage III Mantle Cell Lymphoma
- Stage IV Mantle Cell Lymphoma

## Interventions

- **DRUG:** ibrutinib
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT02242097
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-01-12
- **Primary completion:** 2023-01-05
- **Final completion:** 2025-01
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2024-03-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02242097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02242097, "Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02242097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*